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Abstract

Where one lives affects one’s blood pressure. Observational studies demonstrate
that living in communities of low socioeconomic status is associated with higher blood
pressure and worse cardiovascular outcomes. In understanding the reasons for these
disparities, a key question is whether evidence-based antihypertensive medication therapy
is less effective in lowering blood pressure and improving cardiovascular outcomes in
lower socioeconomic communities. If so, then anti-hypertensive therapies derived from
randomized clinical trials (RCTs) may be suboptimal in achieving expected outcomes.
Despite standardized protocols and balancing of demographic and clinical characteristics
between study arms of RCTs, the socioeconomic environment in which people live is
rarely examined, potentially exerting an unmeasured effect on study outcomes.
To determine the impact of socioeconomic context on response to
antihypertensive medication in clinical trials, we analyzed data from the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest
existing RCT of hypertension treatment. This trial, conducted from 1994 to 2002,
randomized 42,418 people, 55 years or older, with hypertension and at least one other
cardiovascular risk factor, to chlorthalidone, lisinopril, amlodipine or doxazosin (mean
follow-up of 4.9 years). After excluding non-continental U.S. sites and the doxazosin arm
(terminated early in ALLHAT) our study included 27,862 participants. We defined
socioeconomic context by mapping study site ZIP codes to counties and stratifying these
counties into income quintiles based on the national distribution of county median
household income, adjusted for cost-of-living, from the 2000 U.S. census.

We compared baseline and clinical characteristics, visit and medication
adherence, blood pressure control, and cardiovascular outcomes between ALLHAT
participants in the lowest and highest income sites using multivariable regression models.
Participants receiving care in Quintile 1 (Q1, lowest income sites) (n = 2169, 7.8%) were
more likely to be female, black, Hispanic, have fewer total years of education, live in the
South, and have fewer cardiovascular risk factors than participants in Quintile 5 (Q5,
highest income sites) (n = 10458, 37.6%). Compared with Q5, participants in Q1 were
less likely to achieve blood pressure control (<140/90 mmHg) (OR, 0.48; 95% CI, 0.370.63), and experienced higher all-cause mortality (HR, 1.25; 95% CI, 1.10-1.41), heart
failure hospitalizations or mortality (HR, 1.26; 95% CI, 1.03-1.55) and end-stage renal
disease (ESRD) (HR, 1.86; 95% CI, 1.26-2.73), though lower angina hospitalizations
(HR, 0.70; 95% CI, 0.59-0.83) and coronary revascularization (HR, 0.71; 95% CI, 0.570.89). There were no differences in stroke, myocardial infarction, or peripheral arterial
disease.
Despite having access to standardized treatment protocols, participants in the
lowest income sites experienced poorer blood pressure control, higher mortality, ESRD
and heart failure morbidity, and decreased coronary revascularization compared to those
in the highest income sites. These findings suggest a need to better measure and bolster
the socioeconomic context beyond the medical environment to eliminate disparities in
outcomes for RCTs of antihypertensive medications. Understanding these relationships
may guide the generalizability of RCT findings, promote the assessment of participants’
socioeconomic context in clinical trials and hypertension treatment guidelines, and

inform broader strategies for combating hypertension in populations living in low
socioeconomic environments.
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Foreword

This research was conducted during my time as a medical student at the Yale School of
Medicine, with investigators in the Center for Outcomes Research & Evaluation, and in
collaboration with original investigators from the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT). As the lead author, I presented our
findings at the American Heart Association (AHA) Council on Hypertension/AHA
Council on Kidney in Cardiovascular Disease/American Society of Hypertension/Joint
Scientific Sessions 2017, where it was accepted as an oral presentation and received the
AFHRE Travel Award for Patient-Oriented or Clinical Research in Hypertension. A
manuscript is in preparation for submission for publication in the biomedical literature.

Shahu A, Herrin J, Dhruva SS, Desai NR, Krumholz HM, Spatz ES. Abstract 148:
Association of Socioeconomic Context with Blood Pressure Response and
Cardiovascular Outcomes in ALLHAT. Hypertension. 2017;70(Suppl 1):A148-A.
(Abstr.)
Also presented as a poster, under the title: Variation in Blood Pressure Response
and Cardiovascular Outcomes by Socioeconomic Context in ALLHAT. Medical
Student Research Day, Yale School of Medicine, New Haven, CT, 2017.

Shahu A, Herrin J, Dhruva SS, Desai NR, Pressel SL, Davis BR, Krumholz HM, Spatz
ES. Association of Socioeconomic Context with Response to Antihypertensive
Medication in ALLHAT. (in preparation for submission)
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Introduction

Beyond the guidelines: new paradigms in treatment of hypertension
Hypertension, a medical condition wherein arterial blood pressure is persistently
elevated, is one of the most prevalent medical conditions in the world. It is the most
common condition seen in primary care offices and poses a significant public health
challenge, with an estimated global prevalence of 24.6% in 2000 in people aged 20 years
and older, and projections of up to 29.2% in 2025 (1, 2). In the U.S., the prevalence of
hypertension among adults remained stable from 1999 to 2014 (at about 29%), and the
prevalence of controlled hypertension in adults increased from 31.5% to 53.3% from
1999 to 2009; however, in the years since, the proportion of people with controlled
hypertension has plateaued (3). These statistics indicate that while some progress has
been made over the years in treating hypertension, there remains considerable room for
improvement, with millions of Americans still in need of improved blood pressure
control.
Moreover, hypertension also plays a causative role in cardiovascular disease
(myocardial infarction, stroke, heart failure, peripheral vascular disease) as well as renal
disease, and inadequate treatment has been associated with increased mortality (4).
Furthermore, countless studies have shown that treatment of hypertension is vitally
important. For every 10-mmHg reduction in systolic blood pressure (SBP), there is a 22%
reduction in the rates of major cardiovascular disease events, coronary heart disease,
stroke, heart failure, and all-cause mortality (5, 6).
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However, despite the large, well-documented body of evidence emphasizing the
importance and benefits of antihypertensive treatment, the medical community has long
debated thresholds for defining hypertension, modalities for diagnosis and treatment of
hypertension, as well as blood pressure targets. In an effort to standardize treatment for a
common but treatable condition, the first clinical practice guidelines for the treatment of
hypertension were developed in 1977 by the Joint National Committee (JNC) on
Detection, Evaluation, and Treatment of High Blood Pressure, appointed by the National,
Heart, Lung and Blood Institute (NHLBI) (7). This committee of experts offered six key
recommendations in a consensus document, based on a combination of existing evidence
and expert opinion: 1) anyone evaluating blood pressure should have resources available
for referral, confirmation, and follow-up; 2) antihypertensive therapy should be started in
all adults with a diastolic blood pressure (DBP) of 105 mmHg or greater; 3) adults with
DBP between 90 and 104 mmHg should be treated on a case-by-case basis depending on
their cardiovascular risk factors; 4) evaluation of hypertension could usually be limited to
a few baseline tests; 5) providers should take a cost-effective stepped-care approach to
treatment (i.e. begin treatment with one drug, titrate to maximal dose, and add additional
drugs in a step-wise fashion if therapeutic goal is not achieved); and 6) providers should
make plans with patients for long-term control of blood pressure (8). Although existing
data suggested an increased risk from elevated SBP, no recommendations were made
regarding SBP in order to minimize complexity in the guidelines.
Clinical practice guidelines for hypertension management were updated over the
ensuing decades, becoming increasingly comprehensive thanks to evidence from major
observational studies and large clinical trials of antihypertensive medications. Thresholds
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for diagnosis of hypertension grew more stringent, leading to the JNC 7 guidelines,
published in 2003, which defined hypertension in adults as having an average SBP of 140
mmHg or greater or DBP of 90 mmHg or greater (9). Prehypertension was defined as
having an average SBP between 130 and 139 mmHg or DBP between 80 and 89 mmHg.
Greater emphasis was placed on standardization of methods; for example, it was
recommended that office blood pressure be measured with the patient in a seated position
after resting for 5 minutes (9). Lifestyle modifications were recommended for early
treatment of prehypertension or hypertension. Step-wise treatment with antihypertensive
medications was recommended at a threshold of 140 mm Hg SBP or 90 mm Hg DBP
(with a treatment goal of <130/80 mmHg for patients with diabetes and chronic kidney
disease [CKD]), recognizing that many people would likely need more than one
medication. Thiazide diuretics (e.g., chlorthalidone or hydrochlorothiazide) were
recommended as first-line medications, although other medications were also deemed
effective in patients with additional cardiovascular risk: calcium channel blockers (CCBs,
e.g., amlodipine), and angiotensin-converting-enzyme inhibitors (e.g., lisinopril),
angiotensin receptor blockers (ARBs, e.g., losartan), and beta blockers (e.g., metoprolol).
These recommendations were strongly influenced by findings from the then-recent
randomized clinical trial (RCT) titled Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT, described in detail later) (10).
However, about a decade later, some experts questioned the strength of the
evidence supporting the blood pressure treatment recommendations in JNC 7. Moreover,
the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, found that a
more intensive treatment target of 120/80 mmHg, versus the standard 140/90 mmHg in
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low-risk people with diabetes, did not reduce cardiovascular outcomes (11). This led to
the convening of a new guideline committee (JNC 8), which focused their review on 3
questions: does initiating hypertension treatment at specific blood pressure thresholds
improve outcomes; does treating blood pressure to specific blood pressure targets
improve outcomes; and do antihypertensive medications differ in their comparative
benefits and harms on health outcomes (12). In alignment with the evidence, the
published guidelines recommended a treatment threshold of 150/90 mmHg in patients 60
years or older, and 140/90 mmHg for adults younger than 60 years. They determined that
based on the negative trial results of ACCORD and the absence of other data sources,
there was insufficient evidence to support lower treatment targets in people over 60 years
of age, and younger people with CKD or diabetes; this represented a break from past
guidelines and concurrent clinical practice (12). Additionally, after reevaluation of
clinical trial data, thiazide diuretics, ACE inhibitors/ARBs, and calcium channel blockers
were equally recommended as first-line agents, though CCBs and thiazides were
recommended as first-line agents in black adults. The JNC 8 guidelines resulted in
considerable controversy. Critics argued that the absence of data to support more
stringent SBP targets did not necessarily point to an absence of effect, and that until new
data were generated, guideline committees should offer their expert opinion and
providers should use their own clinical judgment when helping patients make decisions
about hypertension treatment (4, 13). It is unknown whether the JNC 8 guidelines had an
impact on clinical practice or outcomes; they were again updated only three years later.
Just after the JNC 8 guidelines were published, the results of two trials of
antihypertensive medications were reported: the Systolic Blood Pressure Intervention
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Trial (SPRINT) and the Heart Outcomes Prevention Evaluation (HOPE)–3 trial (14).
SPRINT enrolled people aged 50 or older at high risk for cardiovascular disease but
without diabetes or prior stroke, and found that patients randomized to a treatment SBP
goal of 120 mmHg experienced fewer cardiovascular events as well as a survival benefit
compared to patients treated to a SBP goal of 140 mmHg (15). HOPE-3 enrolled men
aged 55 or older and women aged 65 or older with an intermediate 10-year risk for
cardiovascular events but no cardiovascular disease, and found that antihypertensive
therapy was not associated with a lower risk of adverse cardiovascular events, as
compared to treatment with a placebo, though benefit was observed in the subgroup in
the highest tertile of baseline systolic blood pressure (16). As, a result, there was a push
to revisit the guidelines.
In response, a joint task force, led by the American College of Cardiology (17)
and American Heart Association (AHA) and including 11 different medical
organizations, assumed the role of developing new guidelines from the NHLBI. In the
most comprehensive hypertension guidelines ever, which were more focused around
class of recommendation and the level of existing evidence, this task force made 106
recommendations on the basis of an extensive systematic literature review (18, 19).
Among them, a blood pressure below systolic of 120 mmHg and diastolic <80 mmHg
was categorized as normal, systolic blood pressure of 120-129 and a diastolic blood
pressure <80 mmHg was categorized as “elevated,” 130-139 mmHg or 80-89 mmHg was
categorized as stage 1 hypertension, and ³140/90 mmHg was categorized as stage 2
hypertension (20). These classifications were reminiscent of the JNC 7 taxonomy,
acknowledging observational data that the risks associated with hypertension start with
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an SBP as low as 110-115 mmHg (2). Moreover, in somewhat of a reversal from the JNC
8 guidelines, antihypertensive medication was recommended for patients with an
estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher
and an SBP ³130 mmHg or DBP ³80 mmHg. Additional emphasis was also placed on
out-of-office blood pressure monitoring (home-based monitoring and 24-hour ambulatory
blood pressure monitoring) and nonpharmacological interventions (21).
These new guidelines promise to radically alter the landscape of hypertension
diagnosis and treatment. If they are incorporated into clinical practice, the impact would
be massive: the prevalence of U.S. adults diagnosed with hypertension would increase
from 31.9% to 45.6%, and among U.S. adults taking blood pressure-lowering medication,
the proportion of people with blood pressure above goal would increase from 39.0% to
54.3% (22). Among U.S. adults aged 45-75, the prevalence of hypertension would rise to
63.0% (70.1 million people). In other countries such as China, the impact would be even
greater, with prevalence rates increasing from 38.0% to 55.0% (23). These statistics
indicate that more people than ever, especially younger adults, would be considered to
have hypertension, to be eligible for antihypertensive medication, and to potentially
require more intensive blood pressure lowering.
With millions of additional Americans newly labeled as having hypertension, the
2017 guidelines raise new concerns about the shortcomings of hypertension management
in the modern medical era. First, even among guidelines produced by different medical
organizations, there is inconsistency. In 2017, the American College of Physicians (ACP)
and American Academy of Family Physicians (ACP/AAFP) recommended that patients
be treated to a goal SBP of 140 or 150 mmHg, depending on age and level of
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cardiovascular risk (24). This disagreement among professional organizations may lead
to additional confusion among clinicians as well as patients. More aggressive
antihypertensive treatment, some experts say, may result in more adverse events– such as
syncope and renal dysfunction – as observed in SPRINT and ACCORD (11, 15, 25).
Moreover, the risk of adverse events observed in SPRINT may be much greater in
clinical practice, since in this trial, blood pressure measurements were attained under
ideal conditions (and thus a target of 120/80 mmHg may represent the lowest possible
blood pressure achieved); targeting 120/80 mmHg using more traditional methods to
measure BP may result in even lower blood pressures and thus, more adverse events (21,
26). Additionally, the burden associated with increasing prescriptions and pill numbers
may not be considered ‘worth it’ to patients, many of whom are already overwhelmed by
polypharmacy (27). For these reasons and others, it is unclear whether the new guidelines
will result in changes in clinical practice. Historically, there are considerable gaps
between guideline recommendations and clinical practice – perhaps because physicians
are unfamiliar with the guidelines, find them impractical to implement in real life, or do
not agree with the recommendations based on their own clinical experience (28). Other
patient- and system-level factors may also impact guideline adoption.
Perhaps most importantly, however, guidelines should be considered to provide
just that – guidance. No matter how comprehensive they are, they are not intended to be
adopted by everyone. By nature, guidelines will always be reductive in that they can
never truly capture the unique combination of medical, personal, and contextual factors
that should be considered in clinical decision making. Guidelines have transformed
medicine to where it is today. They may be helpful in establishing proper methods of
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blood pressure measurement or diagnosis of hypertension, or offering guidance on
approaches to treatment of hypertension. Yet, guidelines alone will not be enough to
reduce the prevalence of hypertension, improve rates of hypertension control, or further
reduce cardiovascular outcomes resulting from hypertension. Debate around what
specific blood pressure goals should be, as well as how these goals should differ and what
medications are optimal for different patient populations will persist, which is why we
must move beyond the guidelines in order to break new ground in the fight against
hypertension, especially given the global impact of hypertension on cardiovascular
outcomes.
In order to make further progress in the treatment of hypertension, future
approaches will need to incorporate precision-based medicine, personalized decisionmaking, and contextual factors contributing to health disparities. In recent years, as
methods to analyze “big data” have improved, new studies have attempted to develop
more personalized approaches to antihypertensive treatment, namely by developing
methods to better characterize heterogeneity in outcomes from large RCTs of
hypertension. One study used advanced modeling techniques to examine heterogeneity in
response to blood pressure treatment in the first 6 months of ALLHAT and discovered
two distinct blood pressure trajectory patterns: immediate responders whose blood
pressure decreased immediately following the start of the trial, and non-immediate
responders whose blood pressure initially rose before declining following the start of
treatment (29). These data may be important for expectation setting and planning
appropriate follow-up. Other studies used patient-level data from SPRINT to develop
prediction models that could allow providers to tailor the intensity of blood pressure
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treatment to the calculated risk and benefit for an individual patient or for a subgroup of
patients (30, 31). By developing a better understanding of how different populations
respond to different medications and developing personalized estimates of risks and
benefits, we may be better able to tailor blood pressure goals and treatment for each
individual rather than implementing a one-size-fits-all approach.
The decision-making process offers yet another opportunity to further personalize
treatment of hypertension. Principles of shared decision-making – which has become
more important in recent years as medicine has shifted away from paternalism and
physician-led decision-making – encourage patients who so desire to take an active role
in their clinical care (32). In sharing with patients the range of reasonable treatment
options, the associated risks and benefits of treatment, and the prognosis with and without
intervention, patients can develop more informed preferences and treatment goals (33).
Here again guidelines fall short in that practically speaking not all patients may be able to
tolerate equally intensive blood pressure lowering or may even seek the same outcome
out of treatment. For some patients, pill-taking is difficult and burdensome – the act of
swallowing pills may even be difficult – making some patients more reluctant than others
to take medications (34). One study found that patients may differ in the disutility (or
burden) they associate with taking an idealized version of statin medications, and that for
some patients this disutility may outweigh the benefits they would receive in lifetime
gain (35). We are currently conducting a similar study using an idealized
antihypertensive medication to better understand the disutility patients associate with
blood pressure-lowering interventions. By using guidelines as a starting point for making
clinical decisions that are more in line with patients’ values, clinicians can empower
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patients to meet their own goals instead of setting them up for failure and difficulties with
medication adherence.
Last, differences in hypertension and hypertension outcomes between different
people are not dependent solely on individual characteristics. While the approaches
described above are important, as with the guidelines, they focus only on targeting factors
at the individual level, and do little to address the community-level factors that contribute
to prevalent disparities in hypertension, blood pressure control, and cardiovascular
outcomes. In order for true progress to be made, we must develop new methods to
investigate and address the contextual factors in which people live and obtain care. Such
contextual factors – socioeconomic status or context, access to school or level of
education, poverty, neighborhood violence, unemployment, access to healthy foods and
exercise, social cohesion, and more – are known to worsen disparities in health outcomes
(36-41). However, in the key studies (i.e. RCTs) used to develop guidelines, calculate
risks and benefits, and base clinical decisions, little attention has been given to how
contextual factors affect outcomes. Until we better characterize these factors, we may
never be able to fully generalize outcomes from clinical studies or mitigate the burden of
hypertension. We have selected one of the most studied contextual factors –
socioeconomic context – in order to better understand how it may impact outcomes from
important studies of hypertension. This will be the main subject of the remainder of this
thesis.
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Socioeconomic context and hypertension outcomes
Where one lives affects one’s health. People living in communities of lower
socioeconomic status historically have had lower income, worse housing, poorer access
to nutrition, more environmental risks, and lower educational or job opportunities, than
their counterparts living in wealthier areas (42). Additionally, studies dating back to the
1980s have shown that people living in these communities experience poorer health and
greater mortality (43, 44). In recent decades, socioeconomic disparities in various health
outcomes have only widened – as measured by differences in median household income,
education level, median housing value, housing occupancy, education level, occupation,
and to some extent, race – suggesting that interventions to improve social risk factors
may result in more equitable outcomes (45-48).
Notably, the effect of the socioeconomic context of a neighborhood, community,
or county on health outcomes is distinct from that of an individual’s socioeconomic
status. Studies have demonstrated that neighborhood– or area–level socioeconomic
deprivation, measured by a combination of factors such as housing indicators, wealth and
income, education, and occupation, leads to worse health outcomes (e.g. incidence of
heart failure, hospital readmissions for heart failure, cancer incidence and mortality, allcause mortality, depression, type 2 diabetes), even after accounting for individual-level
factors such as individual socioeconomic status (39, 49-53). These findings suggest that
person-level factors alone cannot explain disparities in health outcomes, perhaps because
indicators such as area-level income may give a sense of both an individual’s general
socioeconomic status as well as the amount of resources available to the overall
community living in an area. Furthermore, these results underline the need to more
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closely examine the impact that community-level factors such as socioeconomic context
may have on the overall health and well-being of diverse populations.
Where one lives also affects one’s blood pressure. Studies consistently show an
inverse relationship between socioeconomic status and mean blood pressure (54-56).
Moreover, numerous observational studies demonstrate that living in a neighborhood of
lower socioeconomic status is associated with a higher prevalence of hypertension, worse
blood pressure control, and higher rates of sequelae of hypertension, including secondary
heart disease, renal failure and stroke (57-59). In understanding the reasons for these
disparities, a key question is whether antihypertensive medication therapy is less effective
in lowering blood pressure and improving cardiovascular outcomes in lower
socioeconomic communities. If so, then the implementation of evidence-based therapies
for hypertension derived from RCTs may be suboptimal in achieving expected outcomes
in differing socioeconomic populations.
Antihypertensive medication may be less effective when used in low
socioeconomic communities for a number of reasons. Living in an under-resourced
community may be associated with other factors that affect blood pressure, including
unhealthy lifestyle behaviors related to access to food or facilities, poorer perceived
health status, differing cultural norms, or practical barriers to eating healthily, exercising,
and quitting smoking (60-64). Additionally, people living in disadvantaged communities
may experience changes in blood pressure due to an allostatic load resulting from stress
associated with unemployment, housing conditions, mental health, financial burdens,
poor social cohesion, neighborhood safety and violence, and other social ills, further
contributing to disease progression (65-69). In low income communities, access to high-

14
quality primary care is often inadequate, and there may be greater acceptance that
hypertension is inevitable (70-72). This culture can affect people’s sense of control or
capacity to lower their risk of cardiovascular events through regular follow-up,
medication adherence or adoption of lifestyle modifications to halt the progression of
chronic diseases such as hypertension (73-75).
Although relationships between these contextual factors and health outcomes
have been observed and reported in countless observational studies, they are rarely
measured in RCTs; potentially, some contextual factors may be exerting an unmeasured
effect on study outcomes. Specifically, in RCTs, while efforts are made to balance
differences in patient demographic and clinical characteristics, even measurable
indicators of the socioeconomic environments in which people live, such as area-level
income are rarely taken into account. To our knowledge, there are no existing studies of
RCTs of antihypertensive medication therapy which have examined the possible effect of
socioeconomic context on study participants’ response to antihypertensive medication.
Thus, despite the provision of standardized hypertensive care and interventions within
and between study arms in RCTs of antihypertensive medications, unmeasured factors
related to participants’ socioeconomic environments may contribute to heterogeneity in
outcomes and limit the generalizability of research findings to some populations (76, 77).
This is especially problematic because the findings from these RCTs often form the
cornerstone of treatment guidelines and inform the clinical decisions that practicing
physicians make every day. Therefore, investigation of the socioeconomic context in an
RCT may partly explain why the results of RCTs are often not uniformly observed in
real-world settings (78, 79).
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The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial
To examine the effect of socioeconomic context on response to antihypertensive
medication in RCTs, we analyzed data from the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT is the largest randomized,
double-blinded clinical trial of antihypertensive medical therapy ever, conducted from
1994 to 2002 with 42,418 original study participants from 623 clinical sites across the
U.S., Puerto Rico & Virgin Islands, and Canada (10). The study enrolled men and women
³55 years old with untreated or treated systolic and/or diastolic hypertension and at least
one additional cardiovascular risk factor (80).
As the largest ever prospective RCT of antihypertensive treatment, ALLHAT is
the richest and most reliable data source for secondary analysis. The trial population,
considered to be demographically diverse, was comprised of nearly 50% women; black
and Hispanic participants accounted for 36% and 19% of the overall study population,
respectively (81). The study was considered highly generalizable and sampled across a
broad socio-geographic distribution, as it enrolled patients from clinical sites throughout
North America, where blood pressure ascertainment by trained staff was deemed
consistent and reliable (82, 83). High-quality data was obtained through careful
adjudication of enrollment criteria, documentation, and confirmation of 99% of
cardiovascular disease events resulting in death or hospitalization (10). Information was
collected on potential clinical confounders such as visit-to-visit variability (82). Less than
1% of drug identities were revealed to either participants or investigators, supporting the
rigor of blinding (84).
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Additionally, the findings from ALLHAT have been validated, and extended
follow-up data are available for most participants using national administrative databases
(84, 85). The most recent extended follow-up data included fatal outcomes for 98% and
nonfatal outcomes for 65% of participants (86, 87). Key strengths of the study included
its design as a randomized double-blind trial, statistical power enabling detection of
clinically meaningful differences in certain cardiovascular outcomes, a diverse participant
population, and varied primary care-based clinical settings (private practice, community
health center, Veterans Affairs Medical Center, academic centers, and HMOs) (10).
Given that recent guidelines recommend any of the three main classes of antihypertensive
drugs tested in ALLHAT as first-line medications and the majority of patients in the trial
needed multiple medications, no future trial will likely provide such undiluted data of the
effect of first-line antihypertensive agents (85).
ALLHAT participants were assigned to one of four representative antihypertensive medications: a thiazide diuretic (chlorthalidone), an ACE inhibitor
(lisinopril), a calcium channel blocker (amlodipine), or an alpha-adrenergic blocker
(doxazosin) (80). The purpose was to determine whether newer medication classes, such
as ACE inhibitors and calcium channel blockers – which at the time were costlier than
the historically-used thiazide diuretics – were as good or better than thiazides in
preventing adverse cardiovascular outcomes (i.e. fatal coronary heart disease or nonfatal
myocardial infarction) resulting from hypertension (80). The doxazosin arm was stopped
early due to inferior treatment effect, but most participants in the other arms were
followed from 1994 to 2002, with an average of 4.9 years of follow-up (88, 89). The
main findings, published in 2002, showed that neither amlodipine nor lisinopril were
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superior to chlorthalidone in improving all-cause mortality or reducing the risk of major
coronary events (10). Chlorthalidone was superior to amlodipine in preventing heart
failure but not other kinds of cardiovascular disease, and superior to lisinopril in
preventing some cardiovascular events, such as stroke, heart failure and coronary
revascularization.
A follow-up study indicated that blood pressure control was achieved in a
majority of patients regardless of randomization, with mildly improved rates of blood
pressure control in the chlorthalidone group (90). A subsequent comparison of lisinopril
and amlodipine showed that risk for coronary events was similar, but the risks of stroke,
gastrointestinal bleeding, and angioedema were higher for lisinopril, possibly due to less
effective blood pressure control (91). On the basis of cost and overall clinical equivalence
of thiazides – and even superiority in outcomes such as heart failure and blood pressure
control – to ACE inhibitors and calcium channel blockers, investigators recommended
that thiazide diuretics be considered as first-line therapy for treatment of hypertension
(10, 92). These findings were revisited in the context of subsequent subgroup analyses,
meta-analyses, and new clinical trials, but the conclusions remained the same (86).
Meanwhile, a subtrial of ALLHAT was conducted in which participants were randomized
to pravastatin 40 mg or usual care. In that study, pravastatin did not significantly reduce
all-cause mortality or coronary heart disease compared with usual care (93).
The findings from ALLHAT were among the most consequential of any trial of
hypertension ever conducted, going on to heavily influence recommendations made in the
JNC 7 and JNC 8 hypertension guidelines described earlier, and even resulting in an
increase in diuretic prescriptions (9, 12, 94). Numerous follow-up studies and secondary
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post-hoc analyses of ALLHAT data have been published over the past 15 years,
examining the effect of various factors acting at the person level, such as race, sex,
medication adherence, visit adherence, blood pressure control, comorbidities including
diabetes or chronic kidney disease, medication randomization, medication costeffectiveness, statin treatment, and others on study outcomes (29, 82, 83, 85, 87, 95-107).
However, to date no studies of ALLHAT have considered the effect of socioeconomic
context or other community-level contextual factors on study outcomes.
We define socioeconomic context here as the median household income of the
county in which ALLHAT participants obtained their care (e.g. the ALLHAT clinical
sites). Postulating that socioeconomic context, a proxy for unmeasured contextual factors
such as social stressors and lifestyle behaviors, may impact overall treatment response in
the trial, we compared baseline and clinical characteristics, visit and medication
adherence, blood pressure control, and cardiovascular outcomes among ALLHAT
participants of varying socioeconomic context. Understanding the relationship between
socioeconomic context and outcomes can guide the generalizability of RCT findings,
promote the assessment of participants’ socioeconomic context in clinical trials, and
ultimately, inform broader strategies for combating hypertension in populations living in
low socioeconomic environments.
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Statement of purpose

Specific Aim: In this study, I aim to assess the relationship between the socioeconomic
context in which participants obtained clinical care with response to antihypertensive
medication, as measured by blood pressure control and key adverse cardiovascular
outcomes in ALLHAT, the largest-ever RCT of hypertension.

Hypothesis: ALLHAT participants obtaining care in lower income areas will have a
lower likelihood of achieving blood pressure control (defined as a blood pressure less
than 140/90 mmHg) and a higher risk of experiencing the main primary and secondary
adverse cardiovascular outcomes defined in the original trial.
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Methods

Contributions
I, the student, was the intellectual driver of this research. I was responsible for
conducting the literature review, creating the research proposal, formulating a plan for
data acquisition, designing an analytic plan, and working closely with our statistician to
analyze and interpret our data. As the lead author on this project, I was also responsible
for creating all posters and presentations, and writing the resulting manuscript.

Overview
We conducted a secondary analysis of ALLHAT to examine the effect of
socioeconomic context on study outcomes. To measure socioeconomic context, we used
the income level of the county in which the clinical site was located, assuming
participants lived in nearby communities and therefore were exposed to a similar
socioeconomic context as the clinical site. We then assessed the distribution of
participants’ income status compared with the national mean in 2000 (when the trial was
underway), and compared baseline characteristics and outcomes of participants in
quintile 1 (Q1, lowest socioeconomic status) with participants in quintile 5 (Q5, highest
socioeconomic status). To better understand whether demographic factors such as race
and region of care, previously associated with hypertension outcomes but also associated
with socioeconomic status, confounded any differences observed, we also assessed
differences by income quintile among two subgroups, black participants and clinical sites
in the South.
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ALLHAT study design and organization
Details of the rationale, study design, and main findings for ALLHAT have been
explained above and are extensively described in the literature (10, 80, 88). ALLHAT
originally enrolled 42,418 men and women ³55 years old with untreated systolic (defined
as 140 £ 180 mmHg) and/or diastolic (90 £ 110 mmHg) hypertension present on ³2
visits, or treated hypertension (£160/110 mmHg on 1-2 antihypertensive medications at
visit 1 [where participants were assessed for study eligibility] and £180/110 mmHg at
visit 2 [where participants were randomized after stepdown from any pre-study
antihypertensive drugs]) (80). Eligible study participants also had at least one additional
cardiovascular risk factor (80). These risk factors included: history of atherosclerotic
cardiovascular disease (CVD); history of myocardial infarction or stroke; history of
coronary revascularization; other atherosclerotic CVD; history of ST depression or Twave inversion on electrocardiogram (ECG); type 2 diabetes; a high-density lipoprotein
C (HDL-C) of <35 mg/dL at least twice in the five years prior to the trial; left ventricular
hypertrophy (LVH) by ECG in the 2 years prior to the trial; LVH by echocardiogram in
the 2 years prior to the trial; history of coronary heart disease (CHD) at baseline; body
mass index (BMI); aspirin use at the start of the trial; cigarette smoking; and estrogen
supplementation at the time of the trial.
The study was conducted from 1994 to 2002, with a mean of 4.9 years of followup (108). Visit frequency included follow-up at 1 month; 3, 6, 9, and 12 months; and
every 4 months thereafter (more often as needed), which was considered usual for
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hypertension care (10, 85). Patients were assigned to one of four representative antihypertensive medications – a thiazide diuretic (chlorthalidone), an ACE inhibitor
(lisinopril), a calcium channel blocker (amlodipine), or an alpha-adrenergic blocker
(doxazosin, stopped early due to inferior treatment effect) – with discouragement of
mixing therapies (89). Because blood response was one of the main outcomes and most
participants continued to have uncontrolled blood pressure (defined as >140/90 mmHg)
despite titration of the assigned study drug, second-line medications (atenolol, clonidine,
or reserpine) were added as needed in a step-wise fashion (10). Study outcomes were
collected through a variety of means: at follow-up visits, from clinical investigator
reports, or other documentation such as a death certificate or a hospital discharge
summary; 99% of cardiovascular events were documented across all 3 treatment groups
(10). Protocols outlining follow-up visits, treatment procedures, and endpoint
ascertainment have been described elsewhere in the biomedical literature (80, 88).
Participating sites acquired institutional review board (IRB) approval and obtained
written informed consent from all participants (10).
The primary study outcome was coronary heart disease [CHD] (fatal CHD and
nonfatal myocardial infarction [MI] combined). Four major pre-specified secondary
outcomes were also defined: (1) all-cause mortality, (2) stroke, combined CHD (CHD,
coronary revascularization, or hospitalized angina), and (4) combined cardiovascular
disease [CVD] (combined CHD, stroke, other treated angina, heart failure [HF], or
peripheral arterial disease). The original trial investigators also assessed subcomponents
of these major outcomes as well as other pre-specified secondary outcomes, including
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cancer, left ventricular hypertrophy by ECG, hospitalization for GI bleed, end-stage renal
disease (ESRD), quality of life, and health care costs (10).

Income data
ALLHAT data was obtained from the NHLBI’s Biologic Specimen and Data
Repositories Information Coordinating Center (BioLINCC). We did not have access to
the ZIP codes or counties in which participants resided, so we instead used enrollment
site ZIP codes, obtained from the original ALLHAT investigators, and mapped these to
one or more site-specific counties. We selected county-level median household income as
a proxy for the socioeconomic context in which patients received their care, derived from
the 2000 U.S. Census, the closest year to the period in which the study was conducted.
County-level incomes were adjusted for cost of living in each state in the year 2000. If
the ZIP code mapped to more than one county, we calculated the population-weighted
average median income across those counties. County-level incomes were assigned to
study participants at that site. Based on the national distribution of county-level
household median income, individuals were stratified into income quintiles.

Exclusion criteria
We excluded participants enrolled in sites outside of the continental U.S.
(n=5,277), due to potential confounders when comparing socioeconomic context of those
sites with sites in the continental U.S., participants in sites lacking income data (n=304)
and participants randomized to doxazosin (n=9,061 participants). After these exclusions,
a total of 27,826 participants were included in this study (see Figure 1).
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Figure 1. Flow chart of study exclusion criteria

Outcomes
We assessed blood pressure control and major adverse cardiovascular events as
pre-specified in ALLHAT. Blood pressure control was defined as the proportion
achieving the ALLHAT treatment goal of 140/90 in years 1-6, regardless of age (80). The
primary and four key secondary cardiovascular outcomes, defined in ALLHAT, were: (1)
CHD, (2) all-cause mortality, stroke, (4) combined CHD, and (5) combined CVD (each
defined above). We also evaluated the following individual components of these
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outcomes: heart failure, hospitalized/fatal heart failure, angina, coronary
revascularization, peripheral arterial disease, and ESRD.

Statistical Analysis
We compared baseline characteristics, treatment, visit and medication adherence,
unadjusted blood pressure response and unadjusted cardiovascular outcomes of the study
population by income quintile. As captured in the original trial, we defined visit
adherence as the number of attended visits divided by the protocol-determined number of
expected visits in the six-year duration of the trial. Adequate visit adherence was defined
as attending at least 80% of expected visits. We defined adequate medication adherence
as taking at least 80% of study medications at all visits, per participants’ self-report. We
then tested the association between socioeconomic context with blood pressure control
and cardiovascular outcomes in the lowest and highest income quintiles, with the highest
income quintile (Q5) serving as the reference group, using logistic regression and Cox
proportional hazards regression analysis, respectively. In this model, we adjusted for
treatment group, age, sex, qualifying ALLHAT risk factors (see ALLHAT study design
and organization, above), and baseline systolic blood pressure (SBP) and diastolic blood
pressure (DBP), using imputation if study participants had missing values for certain risk
factors.
Next, we performed subgroup analyses of blood pressure response and
cardiovascular outcomes across socioeconomic strata (1) among black participants, and
(2) among participants in the South. Last, to assess whether fidelity to the protocol
explained any of the differences between groups, we performed an exploratory analysis
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adjusting for visit adherence in addition to baseline and clinical characteristics. Though
visit adherence is potentially endogenous with the outcome – that is, patients with a
clinical outcome prior to the six-year endpoint may be more likely to adhere to
subsequent visits – we included it in the final model to assess whether it attenuated the
main differences. There was insufficient data of participants’ medication adherence to
include it in the model. This study was approved by the Yale Human Investigations
Committee.
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Results

Geographic distribution of clinical sites
The 27,826 participants included in this study obtained care in clinical sites
representing 372 U.S. counties, depicted in Figure 2. Nearly all (32/35, 91%) of the
lowest-income counties (Q1) were in the South, whereas the highest-income counties
(Q5) were more evenly distributed across geographic regions.

Figure 2. Geographic distribution and socioeconomic (income) stratification of U.S.
counties with clinical sites participating in ALLHATA

a

Image created using mapchart.net.
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Baseline characteristics
Baseline demographic and clinical characteristics, qualifying risk factors, and
treatment group randomization across income strata in ALLHAT are shown in Table 1.
Participants enrolled in the lowest income sites (Q1, bottom income quintile) comprised
7.8% of the study population, while those enrolled in the highest income sites (Q5, top
income quintile) comprised 37.6% of the study population. Participants in Q1 tended to
be younger, female, black or Hispanic, and had attained lower levels of education than
participants in Q5. The county-level cost-of-living-adjusted median household income
was 2.8 times higher in Q5, as compared to Q1. Participants from the South made up
more than 98% of people in Q1 but only 18.6% of people in Q5. Participants across
economic strata entered the trial with similar clinical characteristics, including similar
baseline blood pressures, GFR, potassium, fasting glucose, and numbers of
antihypertensive medications prior to the trial. Compared to Q5, fewer participants in Q1
had a history of atherosclerotic cardiovascular disease, had ever smoked, or were on
aspirin. A greater proportion of Q1 participants enrolled in the lipid trial portion of
ALLHAT, as well. Participants across strata were equally likely to have type II diabetes.
Additionally, there were similar numbers of participants in each treatment arm across
socioeconomic strata, consistent with randomization.
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Table 1. Baseline characteristics of study population across socioeconomic strata
County income level
Characteristic
Q1A
Q2
Q3
Q4

Q5

N (%) or
Mean (SD)

N (%) or
Mean (SD)

N (%) or
Mean (SD)

N (%) or
Mean (SD)

N (%) or
Mean (SD)

2169
66.1 (8.4)
1285 (59.2)

3562
66.4 (7.4)
1645 (46.2)

4916
67.1 (7.7)
2242 (45.6)

6721
67.1 (7.4)
2899 (43.1)

10458
67.0 (7.5)
4570 (43.7)

242 (11.2)
1524 (70.3)
1 (0.1)
1 (0.1)
401 (18.5)
433 (20.0)

1353 (38.0)
2189 (61.5)
6 (0.2)
2 (0.1)
12 (0.3)
54 (1.5)

3208 (65.3)
1477 (30.0)
20 (0.4)
15 (0.3)
196 (4.0)
332 (6.8)

4121 (61.3)
2432 (36.2)
9 (0.1)
26 (0.4)
133 (2.0)
276 (4.1)

6830 (65.3)
2910 (27.8)
31 (0.3)
322 (3.1)
365 (3.5)
592 (5.7)

1855 (85.5)
163 (7.5)
46 (2.1)

2807 (78.8)
499 (14.0)
111 (3.1)

3383 (68.8)
978 (19.9)
209 (4.3)

4221 (62.8)
1630 (24.3)
373 (5.6)

6090 (58.2)
2924 (28.0)
774 (7.4)

COLA median income ($ k)
21.8 (2.4)
Number of counties
35
Number of participants by geographic region
East
2 (0.1)
South
2134 (98.4)
Midwest
2 (0.1)
West
31 (1.4)

29.2 (1.1)
45

33.0 (1.3)
62

38.2 (1.6)
75

49.6 (8.7)
155

12 (0.3)
3216 (90.3)
322 (9.0)
12 (0.3)

748 (15.2)
3399 (69.1)
510 (10.4)
259 (5.3)

1687 (25.1)
2919 (43.4)
1892 (28.2)
223 (3.3)

2545 (24.3)
1941 (18.6)
3299 (31.6)
2673 (25.6)

145.0 (16.8)
83.7 (10.7)
80.4 (21.8)
1.0 (0.3)
4.3 (0.7)
127.2 (61.7)

145.3 (15.8)
82.9 (10.0)
79.7 (21.3)
1.1 (0.3)
4.3 (0.7)
128.4 (63.0)

145.7 (15.9)
82.3 (10.2)
76.5 (19.2)
1.0 (0.3)
4.3 (0.7)
121.5 (55.3)

147.5 (15.6)
84.1 (9.9)
77.0 (19.6)
1.0 (0.3)
4.3 (0.7)
123.0 (58.7)

145.7 (15.5)
83.7 (10.0)
76.8 (18.9)
1.0 (0.3)
4.4 (0.6)
120.9 (53.1)

1831 (84.4)
58 (2.7)
280 (12.9)

3086 (86.6)
126 (3.5)
350 (9.8)

4270 (86.9)
137 (2.8)
509 (10.4)

5809 (86.4)
273 (4.1)
639 (9.5)

9080 (86.8)
365 (3.5)
1012 (9.7)

904 (41.7)
309 (14.3)
102 (4.7)
398 (18.4)
286 (13.2)
770 (35.5)
72 (3.3)
640 (29.5)
86 (4.0)
14 (0.7)
30.4 (6.4)
568 (26.2)
146 (6.7)
720 (33.2)

1706 (47.9)
876 (24.6)
391 (11.0)
563 (15.8)
448 (12.6)
1450 (40.7)
270 (7.6)
674 (18.9)
117 (3.3)
41 (1.2)
29.9 (6.2)
1186 (33.3)
240 (6.7)
922 (25.9)

2556 (52.0)
1202 (24.5)
780 (15.9)
1117 (22.7)
472 (9.6)
1773 (36.1)
606 (12.3)
692 (14.1)
231 (4.7)
71 (1.4)
29.5 (5.8)
1916 (39.0)
471 (9.6)
1264 (25.7)

3786 (56.3)
1731 (25.8)
986 (14.7)
1792 (26.7)
768 (11.4)
2333 (34.7)
913 (13.6)
977 (14.5)
231 (3.4)
81 (1.2)
30.0 (6.0)
2705 (40.3)
518 (7.7)
1362 (20.3)

5721 (54.7)
2585 (24.7)
1693 (16.2)
2720 (26.0)
1003 (9.6)
3624 (34.7)
1491 (14.3)
1547 (14.8)
568 (5.4)
132 (1.3)
29.7 (6.1)
4089 (39.1)
1059 (10.1)
2303 (22.0)

Demographics
Total participants
Age
Female
Race
White
Black
American Indian
Asian/Pacific Islander
Other
Hispanic
Education
High School or Less
College
Post-graduate

County characteristics

Baseline clinical characteristics
Systolic blood pressure (SBP)
Diastolic blood pressure (DBP)
GFRB
CreatinineB
PotassiumB
Fasting glucoseB
Receiving anti-hypertensive treatment
On 1-2 meds >= 2 months
On meds < 2 months
Untreated at baseline

Qualifying risk factors for ALLHAT
History of atherosclerotic CVDC
History of MI or stroke
History of coronary revascularization
Other atherosclerotic CVD
History of ST dep/T-wave inv
Type II diabetes
HDL-C <35 mg/dL twice in past 5 years
LVH by ECG in past 2 years
LVH by echocardiogram in past 2 years
History of CHD at baseline
BMI
Current aspirin use
Current estrogen supplementationD
Lipid trial participants
Cigarette Smoker
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Current
Past
Never

485 (22.4)
678 (31.3)
1006 (46.4)

907 (25.5)
1338 (37.6)
1317 (37.0)

1114 (22.7)
2046 (41.6)
1755 (35.7)

1531 (22.8)
2963 (44.1)
2227 (33.1)

2173 (20.8)
4616 (44.1)
3668 (35.1)

2254 (45.9)
1333 (27.1)
1329 (27.0)

3077 (45.8)
1807 (26.9)
1837 (27.3)

4774 (45.7)
2851 (27.3)
2833 (27.1)

Treatment Group (antihypertensive randomization group)
Chlorthalidone
Amlodipine
Lisinopril

994 (45.8)
587 (27.1)
588 (27.1)

1625 (45.6)
967 (27.2)
970 (27.2)

Abbreviations: N, number of participants; SD, standard deviation; COLA, cost-of-livingadjusted median income; GFR, glomerular filtration rate; CVD, cardiovascular disease;
MI, myocardial infarction; dep, depression; inv, inversion; HDL, high-density
lipoprotein; LVH, left ventricular hypertrophy; ECG, electrocardiogram; CHD, coronary
heart disease; BMI, body mass index.
A

Q1 represents study participants who obtained care at clinical sites located in counties
that fall into the lowest income quintile nationally. Q5 represents the highest income
quintile.
B
Numbers may not add to total because of missing data.
C
History of atherosclerotic CVD contains the following categories: history of MI or
stroke, history of coronary revascularization, history of major ST segment depression or
T-wave inversion on any ECG in the past 2 years, and other atherosclerotic CVD.
D
Applies to female participants only.

Visit and medication adherence
Table 2 shows differences in visit and medication adherence for participants
across income strata. Participants in Q1 had lower visit adherence (29.7%) than those in
Q5 (40.8%; P<0.001). Adequate medication adherence was also lower among
participants in Q1 (36.3%) compared with participants in Q5 (55.6%; P<0.001). Overall,
both visit and medication adherence were similar for participants in Q2-Q5, though
participants in Q2 had the highest adequate visit adherence (44.6%) and medication
adherence (61.1%). Importantly, data on medication adherence was missing in 21.838.0% of participants in each income quintile, while visit adherence was only missing in
0.8-1.5% of participants in each income quintile.
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Table 2. Visit and medication adherence of study population across socioeconomic strata
County income level
Characteristic
Q1A
Q2
Q3
Q4
Q5
Total participants
Visit adherenceB
< 80%
³ 80%
Missing
Medication adherenceC
Ever < 80%
Always ³ 80%
Missing

N (%)
2169

N (%)
3562

N (%)
4916

N (%)
6721

N (%)
10458

1498 (69.1)
644 (29.7)
27 (1.2)

1946 (54.6)
1588 (44.6)
28 (0.8)

2812 (57.2)
2044 (41.6)
60 (1.2)

4099 (61.0)
2524 (37.6)
98 (1.5)

6085 (58.2)
4264 (40.8)
109 (1.0)

557 (25.7)
788 (36.3)
824 (38.0)

610 (17.1)
2176 (61.1)
776 (21.8)

930 (18.9)
2766 (56.3)
1220 (24.8)

1300 (19.3)
3668 (54.6)
1753 (26.1)

2289 (21.9)
5810 (55.6)
2359 (22.6)

Abbreviations: Q1, lowest income quintile, Q5, highest income quintile; N, number of
participants.
A

Q1 represents study participants who obtained care at clinical sites located in counties
that fall into the lowest income quintile nationally. Q5 represents the highest income
quintile.
B
Visit adherence was defined as the number of visits at six years divided by the number
of expected visits. Adequate visit adherence was defined as attending ³80% of expected
visits.
C
Adequate medication adherence was defined as always taking ³80% of medications
(self-reported by participants).

Blood pressure control
To assess blood pressure response across socioeconomic strata, we first compared
absolute and relative changes in blood pressure between participants in the two income
groups. Participants in Q1 on average experienced a smaller decrease in SBP (-2.6
mmHg) and DBP (-5.8 mmHg) than those in Q5 (SBP, -12.1 mmHg; DBP, -9.9 mmHg)
during the trial (P<0.001). By the end of the trial, Q1 participants had an average blood
pressure of 140/78; meanwhile, participants in Q5 had an average blood pressure of
133/74 (Tables 3A-B). We then calculated the unadjusted rates of participants achieving
blood pressure control (<140/90 mmHg) across socioeconomic groups and treatment
arms (Tables 4A-D). Blood pressure control was substantially lower in Q1 than in the

32
remaining income quintiles (Q2-5). Overall, by year 6 of the trial, 50.0% of participants
in Q1 had attained blood pressure control, as compared with 70.2% of participants in Q5.
Notably, the share of Q1 participants who attained blood pressure control plateaued at
50% after year 3 or 4; on the other hand, for Q5 participants, this percentage increased
year after year. These results were similar for each of the treatment arms. Finally, we
compared the likelihood of achieving blood pressure control in Q1 and Q5 participants,
adjusting for baseline demographics, clinical characteristics, risk factors, and treatment
arm, with Q5 serving as the reference group (Table 5). Participants in Q1 were
significantly less likely to achieve blood pressure control than those in Q5 after 1 year in
the trial (44.8% vs 57.3%; OR, 0.63; 95% CI, 0.56-0.70), a difference which persisted
each year of the trial and even increased after 6 years (50.0% vs 69.3%; OR, 0.48; 95%
CI, 0.37-0.63).

Table 3A. Mean blood pressure at years 1-6, stratified by income level
County Income Level
Outcome
Q1
Q2
Q3
Q4
Mean (SD)
Systolic blood pressure
Year 1
140.5 (18.6)
Year 2
140.8 (19.1)
Year 3
139.8 (18.4)
Year 4
138.5 (18.4)
Year 5
138.3 (19.0)
Year 6
139.9 (21.3)
Diastolic blood pressure
Year 1
80.8 (11.1)
Year 2
80.0 (10.8)
Year 3
78.8 (10.5)
Year 4
78.7 (10.9)
Year 5
78.5 (11.1)
Year 6
78.2 (11.5)

Q5

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

139.5 (16.9)
138.2 (16.3)
136.5 (16.6)
136.3 (17.0)
135.9 (16.7)
135.2 (17.6)

138.4 (17.3)
137.0 (17.2)
135.7 (16.6)
134.9 (16.5)
134.7 (16.7)
134.6 (16.1)

138.9 (16.2)
137.6 (16.2)
136.2 (16.2)
135.1 (16.3)
134.4 (15.6)
133.4 (15.9)

137.7 (16.0)
136.7 (15.9)
135.4 (15.5)
134.1 (15.3)
134.0 (14.9)
133.2 (15.9)

79.3 (9.9)
78.4 (9.9)
77.1 (10.0)
76.6 (9.9)
75.6 (10.0)
73.8 (10.6)

78.1 (10.1)
77.3 (10.5)
76.3 (10.3)
75.5 (10.2)
74.4 (10.6)
73.6 (10.2)

79.6 (9.8)
78.2 (9.9)
76.7 (10.3)
75.9 (10.0)
74.3 (10.0)
73.4 (9.8)

79.2 (9.8)
78.1 (9.7)
76.8 (9.6)
76.0 (9.8)
75.1 (9.8)
74.0 (10.0)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; SD, standard
deviation.
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Table 3B. Mean change in blood pressure from baseline at years 1-6, stratified by income
level
County Income Level
Outcome
Q1
Q2
Q3
Q4
Q5
Mean (SD)
Mean (SD)
Mean (SD)
Change in systolic blood pressure compared with baseline
Year 1
-4.0 (21.5)
-5.7 (19.2)
-7.1 (20.1)
Year 2
-3.2 (22.5)
-6.9 (19.6)
-8.5 (21.1)
Year 3
-4.3 (21.8)
-8.5 (20.5)
-9.8 (20.4)
Year 4
-5.3 (21.7)
-8.5 (20.9)
-10.5 (20.6)
Year 5
-4.6 (21.8)
-9.2 (20.7)
-11.1 (21.2)
Year 6
-2.6 (24.5)
-9.8 (21.6)
-10.9 (20.5)
Change in diastolic blood pressure compared with baseline
Year 1
-2.7 (12.1)
-3.5 (10.6)
-4.2 (11.3)
Year 2
-3.4 (12.2)
-4.3 (11.2)
-5.0 (11.8)
Year 3
-4.7 (12.1)
-5.5 (11.8)
-6.0 (12.1)
Year 4
-4.9 (12.3)
-6.0 (11.7)
-6.7 (12.2)
Year 5
-5.2 (12.3)
-7.1 (11.6)
-7.8 (12.8)
Year 6
-5.8 (12.8)
-8.7 (12.0)
-8.4 (12.5)

Mean (SD)

Mean (SD)

-8.4 (19.3)
-9.6 (19.2)
-11.0 (20.0)
-11.9 (20.0)
-12.4 (19.9)
-13.1 (20.1)

-7.8 (19.0)
-8.7 (19.1)
-9.9 (19.1)
-11.1 (19.3)
-11.3 (19.5)
-12.1 (20.3)

-4.4 (10.9)
-5.9 (11.1)
-7.4 (11.6)
-8.1 (11.4)
-9.2 (11.3)
-10.4 (11.4)

-4.4 (10.7)
-5.5 (11.0)
-6.8 (11.0)
-7.5 (11.3)
-8.6 (11.4)
-9.9 (11.6)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; SD, standard
deviation.

Table 4A. Blood pressure controlA for all treatment groups combined, stratified by
income level
County Income Level
Outcome
Q1
Q2
Q3
Q4
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

N (%)
786 (44.8)
695 (45.2)
657 (48.1)
561 (50.2)
344 (51.2)
140 (50.0)

N (%)
1625 (51.2)
1578 (54.7)
1580 (59.8)
1489 (62.0)
1055 (63.9)
575 (64.3)

N (%)
2299 (54.9)
2170 (57.6)
2099 (61.0)
1950 (63.4)
1224 (65.0)
677 (64.7)

N (%)
3037 (53.2)
2916 (57.1)
2867 (61.3)
2734 (64.8)
1635 (67.5)
956 (71.6)

Q5

N (%)
5284 (57.3)
5073 (59.6)
4950 (63.6)
4715 (67.1)
2874 (68.0)
1499 (69.3)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of
participants.
A

Blood pressure control is represented as the unadjusted number or percentage of
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT,
for each income level.
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Table 4B. Blood pressure controlA for chlorthalidone treatment arm
County Income Level
Outcome
Q1
Q2
Q3
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

N (%)
394 (48.9)
356 (50.7)
325 (51.8)
274 (53.4)
153 (50.2)
63 (50.0)

N (%)
787 (53.5)
783 (57.9)
780 (63.2)
736 (65.8)
510 (67.3)
278(69.7)

N (%)
1103 (57.1)
1049 (60.0)
997 (62.7)
911 (63.5)
577 (65.9)
310 (64.0)

Q4

Q5

N (%)
1490 (56.7)
1432 (60.2)
1360 (62.8)
1299 (67.0)
779 (69.8)
454 (72.2)

N (%)
2522 (59.7)
2437 (62.1)
2317 (64.6)
2196 (67.9)
1392 (71.1)
694 (70.2)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of
participants.
A

Blood pressure control is represented as the unadjusted number or percentage of
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT,
for each income level.
Table 4C. Blood pressure controlA for amlodipine treatment arm
County Income Level
Outcome
Q1
Q2
Q3
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

N (%)
197 (41.8)
171 (41.0)
179 (47.7)
148 (47.4)
100 (54.1)
37 (46.3)

N (%)
455 (52.7)
427 (54.9)
437 (60.0)
395 (59.8)
308 (65.1)
162 (60.9)

N (%)
610 (53.6)
580 (56.3)
574 (60.5)
553 (64.8)
349 (65.1)
203 (67.4)

Q4

Q5

N (%)
799 (52.5)
788 (57.6)
782 (61.8)
740 (64.2)
444 (67.1)
254 (71.3)

N (%)
1472 (58.3)
1368 (58.7)
1411 (65.7)
1336 (68.4)
800 (68.3)
405 (68.3)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; BP, N, number
of participants.
A

Blood pressure control is represented as the unadjusted number or percentage of
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT,
for each income level.
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Table 4D. Blood pressure controlA for lisinopril treatment arm
County Income Level
Outcome
Q1
Q2
Q3
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

N (%)
195 (40.8)
168 (40.2)
153 (42.1)
139 (47.4)
91 (50.0)
40 (54.1)

N (%)
383 (45.7)
368 (48.6)
363 (53.5)
358 (57.5)
237 (56.4)
135 (59.0)

N (%)
586 (52.5)
541 (54.8)
528 (58.5)
486 (61.5)
298 (63.1)
164 (62.8)

Q4

Q5

N (%)
748 (48.1)
696 (51.2)
725 (58.4)
695 (61.6)
412 (63.8)
248 (70.7)

N (%)
1290 (52.3)
1268 (56.1)
1222 (59.7)
1183 (64.3)
682 (62.2)
400 (68.8)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of
participants.
A

Blood pressure control is represented as the unadjusted number or percentage of
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT,
for each income level.

Table 5. Association between income and blood pressure control across income strata
County Income Level
Low Income Effect
Outcome
Q1
Q5
Risk-Adjusted ORA
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

% with BP <140/90 mmHg
44.8
45.2
48.1
50.2
51.2
50.0

% with BP <140/90 mmHg
57.3
59.6
63.6
67.1
68.0
69.3

OR (95% CI)
0.63 (0.56-0.70)
0.58 (0.52-0.66)
0.55 (0.49-0.62)
0.53 (0.46-0.60)
0.51 (0.43-0.61)
0.48 (0.37-0.63)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio;
BP, blood pressure; CI, confidence interval.
A

Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90
mmHg), with the highest income quintile, Q5, serving as the reference group. Model
adjusts for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors
for ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization,
history of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II
diabetes, history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35
mg/dL, LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen
supplementationB).
B
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.
Among black participants, we observed similar trends in attainment of target
blood pressure between economic strata (Table 6A); black participants receiving care in
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Q1 were less likely than black participants receiving care in Q5 to achieve blood pressure
control after 1 year (OR, 0.70; 95% CI, 0.61-0.81) and each year through year 6 (OR,
0.53; 95% CI, 0.38-0.74). Similarly, among clinical sites located in the South,
participants in Q1 were less likely to achieve blood pressure control each year including
year 1 (OR, 0.66; 95% CI, 0.56-0.77) and year 6 (OR, 0.51; 95% CI, 0.34-0.76)
compared with participants in Q5 (Table 6B). In the exploratory analyses, which
included visit adherence in the model, results were unchanged (Table 7). Participants in
Q1 were less likely to achieve blood pressure control, even when visit adherence was
taken into account, at year 1 (OR, 0.63; 95% CI, 0.57-0.70) and year 6 (OR, 0.48; 95%
CI, 0.36-0.62).

Table 6A. Association between income and blood pressure control among black
ALLHAT participants across socioeconomic strata
County Income Level
Low Income Effect
Outcome
Q1
Q5
Risk-Adjusted ORA
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

% with BP <140/90 mmHg
43.5
44.8
46.4
50.8
49.1
46.5

% with BP <140/90 mmHg
51.7
52.8
57.6
61.3
63.7
63.2

OR (95% CI)
0.70 (0.61-0.81)
0.73 (0.62-0.85)
0.65 (0.55-0.76)
0.69 (0.58-0.82)
0.55 (0.44-0.69)
0.53 (0.38-0.74)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio;
BP, blood pressure; CI, confidence interval.
A

Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90
mmHg), with the highest income quintile, Q5, serving as the reference group. Model
adjusts for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors
for ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization,
history of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II
diabetes, history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35
mg/dL, LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen
supplementationB).
B
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.
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Table 6B. Association between income and blood pressure control among ALLHAT
participants living in the South across socioeconomic strata
County Income Level
Low Income Effect
Outcome
Q1
Q5
Risk-Adjusted ORA
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

% with BP <140/90 mmHg
44.5
44.9
47.5
49.9
50.9
50.0

% with BP <140/90 mmHg
57.6
57.0
60.4
63.7
62.3
69.7

OR (95% CI)
0.66 (0.56-0.77)
0.72 (0.61-0.85)
0.63 (0.53-0.75)
0.61 (0.51-0.74)
0.67 (0.52-0.86)
0.51 (0.34-0.76)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio;
BP, blood pressure; CI, confidence interval.
A

Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90
mmHg), with the highest income quintile, Q5, serving as the reference group. Model
adjusts for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors
for ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization,
history of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II
diabetes, history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35
mg/dL, LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen
supplementationB).
B
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.
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Table 7. Association between income and blood pressure control across socioeconomic
strata, adjusted for visit adherence
County Income Level
Low Income Effect
Outcome
Q1
Q5
Risk-Adjusted ORA
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6

% with BP <140/90 mmHg
44.8
45.2
48.1
50.2
51.2
50.0

% with BP <140/90 mmHg
57.3
59.6
63.6
67.1
68.0
69.3

OR (95% CI)
0.63 (0.57, 0.70)
0.58 (0.52, 0.66)
0.55 (0.49, 0.63)
0.53 (0.46, 0.60)
0.52 (0.44, 0.63)
0.48 (0.36, 0.62)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio;
BP, blood pressure; CI, confidence interval.
A

Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90
mmHg), with the highest income quintile, Q5, serving as the reference group. Model
adjusts for treatment group, age, sex, baseline SBP and DBP, qualifying risk factors for
ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization, history
of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes,
history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35 mg/dL,
LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen
supplementationB), and six year visit adherenceB.
B
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.

Cardiovascular outcomes
We then compared rates of pre-specified time-to-event cardiovascular outcomes
that occurred throughout the trial, across socioeconomic strata and treatment arms
(Tables 8A-D). The rate of the primary outcome, CHD, was lower in Q1 than in Q5
overall (6.9% vs 9.6%); this was consistent across the treatment groups. Fewer
participants in Q1 (compared with Q5) received coronary revascularization (4.2% vs
8.7%) or were hospitalized or treated for angina (6.7% vs 12.4%). However, after
calculating the likelihood of attaining these cardiovascular outcomes and adjusting for
baseline characteristics and treatment arm, there was no significant difference in CHD,
between participants in Q1 and Q5 (HR, 0.93; 95% CI, 0.78-1.11) (Table 9). Moreover,
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after risk adjustments were made, participants in Q1 experienced significantly higher allcause mortality (HR, 1.25; 95% CI, 1.10-1.41), heart failure hospitalization/mortality
(HR, 1.26; 95% CI, 1.03-1.55) and ESRD (HR, 1.86; 95% CI, 1.26-2.73). Participants in
Q1 also had lower likelihood of angina treatment/hospitalization (HR, 0.70; 95% CI,
0.59-0.83), combined CVD (HR, 0.89; 95% CI, 0.81-0.99) and coronary
revascularization (HR, 0.71; 95% CI, 0.57-0.89). There were no significant differences in
combined CHD, stroke, diagnosis of new onset heart failure, or peripheral arterial
disease.
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Table 8A. Adverse time-to-event unadjusted cardiovascular outcomes, for all treatment
groups combined, separated by income level
County Income Level
Outcome
Q1
Q2
Q3
Q4
Q5
Primary outcome
CHDA
Secondary Outcomes
All-cause mortality
Combined CHDB
Stroke
Combined CVDC
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaD
Coronary revascularization
Peripheral arterial diseaseE,F,G
ESRD

N (%)

N (%)

N (%)

N (%)

N (%)

150 (6.9)

374 (10.5)

494 (10.0)

699 (10.4)

1000 (9.6)

342 (15.8)
264 (12.2)
107 (4.9)
475 (21.9)

596 (16.7)
631 (17.7)
220 (6.2)
1065 (29.9)

833 (16.9)
932 (19.0)
247 (5.0)
1521 (30.9)

1066 (15.9)
1269 (18.9)
332 (4.9)
1987 (29.6)

1571 (15.0)
1868 (17.9)
492 (4.7)
3077 (29.4)

140 (6.5)
125 (5.8)
146 (6.7)
91 (4.2)
48 (2.2)
38 (1.8)

290 (8.1)
218 (6.1)
379 (10.6)
275 (7.7)
153 (4.3)
62 (1.7)

358 (7.3)
290 (5.9)
632 (12.9)
469 (9.5)
209 (4.3)
62 (1.3)

522 (7.8)
447 (6.7)
825 (12.3)
625 (9.3)
204 (3.0)
130 (1.9)

739 (7.1)
572 (5.5)
1299 (12.4)
909 (8.7)
397 (3.8)
120 (1.1)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, endstage renal disease.
A

CHD: fatal CHD or nonfatal MI combined.
Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina.
C
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
D
Angina includes both hospitalized and treated angina.
E
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
F
The following secondary outcomes are not included in this table: cancer, hospitalized
for GI bleeding.
G
The following component of secondary outcomes was not included in this table: angina
(hospitalized).
B
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Table 8B. Adverse cardiovascular outcomes for chlorthalidone treatment arm
Outcome
Primary outcome
CHDA
Secondary Outcomes
All-cause mortality
Combined CHDB
Stroke
Combined CVDC
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaD
Coronary revascularization
Peripheral arterial diseaseE
ESRDF,G

Q1

County Income Level
Q2
Q3
Q4

Q5

N (%)

N (%)

N (%)

N (%)

N (%)

74 (7.4)

162 (10.0)

225 (10.0)

327 (10.6)

468 (9.8)

171 (17.2)
125 (12.6)
49 (4.9)
214 (21.5)

270 (16.6)
275 (16.9)
89 (5.5)
451 (27.8)

378 (16.8)
428 (19.0)
94 (4.2)
694 (30.8)

498 (16.2)
567 (18.4)
160 (5.2)
883 (28.7)

734 (15.4)
860 (18.0)
231 (4.8)
1374 (28.8)

54 (5.4)
48 (4.8)
64 (6.4)
46 (4.6)
19 (1.9)
16 (1.6)

112 (6.9)
83 (5.1)
172 (10.6)
115 (7.1)
73 (4.5)
20 (1.2)

162 (7.2)
135 (6.0)
287 (12.7)
206 (9.1)
105 (4.7)
30 (1.3)

216 (7.0)
188 (6.1)
358 (11.6)
271 (8.8)
96 (3.1)
65 (2.1)

276 (5.8)
224 (4.7)
578 (12.1)
399 (8.4)
183 (3.8)
53 (0.9)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, endstage renal disease.
A

CHD: fatal CHD or nonfatal MI combined.
Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina.
C
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
D
Angina includes both hospitalized and treated angina.
E
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
F
The following secondary outcomes are not included in this table: cancer, hospitalized
for GI bleeding.
G
The following component of secondary outcomes was not included in this table: angina
(hospitalized).
B
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Table 8C. Adverse cardiovascular outcomes for amlodipine treatment arm
County Income Level
Outcome
Q1
Q2
Q3
Q4
Primary outcome
CHDA
Secondary Outcomes
All-cause mortality
Combined CHDB
Stroke
Combined CVDC
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaD
Coronary revascularization
Peripheral arterial diseaseE
ESRDF,G

Q5

N (%)

N (%)

N (%)

N (%)

N (%)

41 (7.0)

107 (11.1)

136 (10.2)

203 (11.2)

248 (8.7)

85 (14.5)
68 (11.6)
31 (5.3)
128 (21.8)

159 (16.4)
173 (17.9)
50 (5.2)
292 (30.2)

221 (16.6)
256 (19.2)
64 (4.8)
412 (30.9)

284 (15.7)
363 (20.1)
88 (4.9)
558 (30.9)

417 (14.6)
483 (16.9)
123 (4.3)
833 (29.2)

45 (7.7)
41 (7.0)
38 (6.5)
27 (4.6)
14 (2.4)
12 (2.0)

99 (10.2)
78 (8.1)
100 (10.3)
77 (8.0)
35 (3.6)
26 (2.7)

106 (8.0)
85 (6.5)
168 (12.6)
136 (10.2)
48 (3.6)
15 (1.1)

106 (9.0)
142 (7.9)
230 (12.7)
179 (9.9)
52 (2.9)
31 (1.7)

239 (8.4)
184 (6.5)
349 (12.2)
251 (8.8)
99 (3.5)
36 (1.3)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, endstage renal disease.
A

CHD: fatal CHD or nonfatal MI combined.
Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina.
C
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
D
Angina includes both hospitalized and treated angina.
E
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
F
The following secondary outcomes are not included in this table: cancer, hospitalized
for GI bleeding.
G
The following component of secondary outcomes was not included in this table: angina
(hospitalized).
B
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Table 8D. Adverse cardiovascular outcomes for lisinopril treatment arm
County Income Level
Outcome
Q1
Q2
Q3
Q4
Primary outcome
CHDA
Secondary Outcomes
All-cause mortality
Combined CHDB
Stroke
Combined CVDC
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaD
Coronary revascularization
Peripheral arterial diseaseE
ESRDF,G

Q5

N (%)

N (%)

N (%)

N (%)

N (%)

35 (6.0)

105 (10.8)

133 (10.0)

169 (9.2)

284 (10.0)

86 (14.6)
71 (12.1)
27 (4.6)
133 (22.6)

167 (17.2)
183 (18.9)
81 (8.4)
322 (33.2)

234 (17.6)
248 (18.7)
89 (6.7)
415 (31.2)

284 (15.5)
339 (18.5)
84 (4.6)
546 (29.7)

420 (14.8)
525 (18.5)
138 (4.9)
870 (30.7)

41 (7.0)
36 (6.1)
44 (7.5)
18 (3.1)
15 (2.6)
10 (1.7)

79 (8.1)
57 (5.9)
107 (11)
83 (8.6)
45 (4.6)
16 (1.6)

90 (6.8)
69 (5.2)
177 (13.3)
127 (9.6)
56 (4.2)
17 (1.3)

143 (7.8)
117 (6.4)
237 (12.9)
175 (9.5)
56 (3.0)
34 (1.9)

224 (7.9)
164 (5.8)
372 (13.1)
259 (9.1)
115 (4.1)
41 (1.4)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, endstage renal disease.
A

CHD: fatal CHD or nonfatal MI combined.
Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina.
C
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
D
Angina includes both hospitalized and treated angina.
E
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
F
The following secondary outcomes are not included in this table: cancer, hospitalized
for GI bleeding.
G
The following component of secondary outcomes was not included in this table: angina
(hospitalized).
B
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Table 9. Association between income and cardiovascular outcomes across income strata
County Income Level Low Income Effect
Outcome
Q1
Q5 Risk-Adjusted HRA
Primary outcome
CHDB
Secondary outcomes
All-cause mortality
Combined CHDC
Stroke
Combined CVDD
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaE
Coronary revascularization
Peripheral arterial diseaseF
ESRDG,H

Incidence, %

Incidence, %

HR (95% CI)

6.9

9.6

0.93 (0.78-1.11)

15.8
12.2
4.9
21.9

15.0
17.9
4.7
29.4

1.25 (1.10-1.41)
0.89 (0.78-1.01)
1.16 (0.93-1.45)
0.89 (0.81-0.99)

6.5
5.8
6.7
4.2
2.2
1.8

7.1
5.5
12.4
8.7
3.8
1.1

1.07 (0.88-1.29)
1.26 (1.03-1.55)
0.70 (0.59-0.83)
0.71 (0.57-0.89)
0.87 (0.64-1.18)
1.86 (1.26-2.73)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular
disease; ESRD, end-stage renal disease.
A

Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts
for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors for
ALLHAT (BMII, history of MI or stroke, history of coronary revascularization, history of
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes,
history of major ST depression or T-wave inversionI, aspirin use, HDL-C < 35 mg/dL,
LVH by ECG, LVH by echocardiogramI, cigarette smokingI, and estrogen
supplementationI).
B
CHD: fatal CHD or nonfatal MI combined.
C
Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization,
hospitalized angina.
D
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
E
Angina includes both hospitalized and treated angina.
F
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
G
The following secondary outcomes from ALLHAT are not included: cancer,
hospitalized for GI bleeding.
H
The following components of secondary outcomes was not included in this table:
angina (hospitalized).
I
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.
Among black participants, those in Q1 still had higher all-cause mortality after
risk adjustment (HR, 1.24; 95% CI, 1.06-1.44), and greater (although not significant)
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hospitalized/fatal heart failure (HR, 1.29; 95% CI, 0.99-1.68) and ESRD (HR, 1.47; 95%
CI, 0.91-2.36). They also had lower angina treatment/hospitalization (HR, 0.69; 95% CI,
0.55-0.87) and coronary revascularization (HR, 0.69; 95% CI, 0.48-0.99) (Table 10A).
There were no significant differences between income groups among black participants
for other outcomes, including CHD, combined CHD, stroke, combined CVD, new-onset
heart failure, or peripheral arterial disease. Among participants in the South, the risk of
adverse cardiovascular outcomes followed similar trends as the overall study population
(Table 10B). Southern participants in Q1 were more likely to experience all-cause
mortality (HR, 1.14; 95% CI, 0.96-1.36) and ESRD (HR, 1.57; 95% CI, 0.87-2.82), and
less likely to have angina (HR, 0.81; 95% CI, 0.64-1.03) and receive coronary
revascularization (HR, 0.76; 95% CI, 0.57-1.01). However, none of these findings were
statistically significant.
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Table 10A. Association between income and time to cardiovascular outcomes among
black ALLHAT participants across socioeconomic strata
County Income Level Low Income Effect
Outcome
Q1
Q5 Risk-Adjusted HRA
Primary outcome
CHDB
Secondary outcomes
All-cause mortality
Combined CHDC
Stroke
Combined CVDD
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaE
Coronary revascularization
Peripheral arterial diseaseF
ESRDG,H

Incidence, %

Incidence, %

HR (95% CI)

7.0

8.5

0.90 (0.71-1.14)

17.8
11.2
5.2
22.1

15.9
14.4
5.5
26.8

1.24 (1.06-1.44)
0.89 (0.74-1.07)
1.07 (0.81-1.41)
0.90 (0.79-1.03)

6.9
6.0
6.3
2.8
2.1
2.0

6.7
5.3
10.3
4.8
3.3
1.6

1.18 (0.92-1.50)
1.29 (0.99-1.68)
0.69 (0.55-0.87)
0.69 (0.48-0.99)
0.75 (0.49-1.13)
1.47 (0.91-2.36)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular
disease; ESRD, end-stage renal disease.
A

Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts
for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors for
ALLHAT (BMII, history of MI or stroke, history of coronary revascularization, history of
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes,
history of major ST depression or T-wave inversionI, aspirin use, HDL-C < 35 mg/dL,
LVH by ECG, LVH by echocardiogramI, cigarette smokingI, and estrogen
supplementationI).
B
CHD: fatal CHD or nonfatal MI combined.
C
Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization,
hospitalized angina.
D
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
E
Angina includes both hospitalized and treated angina.
F
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
G
The following secondary outcomes from ALLHAT are not included: cancer,
hospitalized for GI bleeding.
H
The following component of secondary outcomes was not included in this table: angina
(hospitalized).
I
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.
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Table 10B. Association between income and time to cardiovascular event outcomes
among participants in ALLHAT living in the South across socioeconomic strata
County Income Level Low Income Effect
Outcome
Q1
Q5 Risk-Adjusted HRA
Primary outcome
CHDB
Secondary outcomes
All-cause mortality
Combined CHDC
Stroke
Combined CVDD
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaE
Coronary revascularization
Peripheral arterial diseaseF
ESRDG,H

Incidence, %

Incidence, %

HR (95% CI)

6.8

9.0

0.94 (0.73-1.19)

15.8
12.1
5.0
21.8

14.7
16.4
4.2
26.7

1.14 (0.96-1.36)
0.94 (0.78-1.13)
1.22 (0.89-1.68)
0.92 (0.80-1.06)

6.4
5.8
6.7
4.3
2.2
1.7

7.3
5.7
10.5
8.1
3.3
1.1

0.93 (0.71-1.20)
1.09 (0.82-1.45)
0.81 (0.64-1.03)
0.76 (0.57-1.01)
1.02 (0.68-1.55)
1.57 (0.87-2.82)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular
disease; ESRD, end-stage renal disease.
A

Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts
for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors for
ALLHAT (BMII, history of MI or stroke, history of coronary revascularization, history of
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes,
history of major ST depression or T-wave inversionI, aspirin use, HDL-C < 35 mg/dL,
LVH by ECG, LVH by echocardiogramI, cigarette smokingI, and estrogen
supplementationI).
B
CHD: fatal CHD or nonfatal MI combined.
C
Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization,
hospitalized angina.
D
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
E
Angina includes both hospitalized and treated angina.
F
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
G
The following secondary outcomes from ALLHAT are not included: cancer,
hospitalized for GI bleeding.
H
The following component of secondary outcomes was not included in this table: angina
(hospitalized).
I
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.
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In exploratory analyses adjusting for visit adherence, results also followed similar
trends, but all-cause mortality (HR, 1.03; 95% CI, 0.91-1.16) and heart failure
treatment/hospitalizations (HR, 1.19; 95% CI, 0.97-1.46) were no longer significantly
greater among Q1 participants (Table 11). Other outcomes were unchanged from the
main findings. ESRD was still significantly higher among Q1 participants (HR, 1.70;
95% CI, 1.16-2.51). As before, participants in Q1 were less likely to have angina (HR,
0.69; 95% CI, 0.58-0.83) and receive coronary revascularization (HR, 0.70; 95% CI,
0.56-0.88).
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Table 11. Association between income and time to cardiovascular event outcomes across
economic strata, adjusted for visit adherence
County Income Level
Low Income Effect
Outcome
Q1
Q5 Risk-Adjusted HRA
Primary outcome
CHDB
Secondary outcomes
All-cause mortality
Combined CHDC
Stroke
Combined CVDD
Components of secondary outcomes
Heart Failure
Hospitalized/fatal heart failure
AnginaE
Coronary revascularization
Peripheral arterial diseaseF
ESRDG,H

Incidence, %

Incidence, %

HR (95% CI)

6.9

9.6

0.87 (0.72,1.04)

15.8
12.2
4.9
21.9

15.0
17.9
4.7
29.4

1.03 (0.91,1.16)
0.85 (0.74,0.97)
1.06 (0.85,1.32)
0.86 (0.78,0.95)

6.5
5.8
6.7
4.2
2.2
1.8

7.1
5.5
12.4
8.7
3.8
1.1

1.01 (0.84,1.23)
1.19 (0.97,1.46)
0.69 (0.58,0.83)
0.70 (0.56,0.88)
0.86 (0.63,1.17)
1.70 (1.16,2.51)

Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular
disease; ESRD, end-stage renal disease.
A

Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts
for treatment group, age, sex, baseline SBP and DBP, qualifying risk factors for
ALLHAT (BMIi, history of MI or stroke, history of coronary revascularization, history of
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes,
history of major ST depression or T-wave inversioni, aspirin use, HDL-C < 35 mg/dL,
LVH by ECG, LVH by echocardiogrami, cigarette smokingi, and estrogen
supplementationi), and six year visit adherencei.
B
CHD: fatal CHD or nonfatal MI combined.
C
Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization,
hospitalized angina.
D
Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral
artery disease.
E
Angina includes both hospitalized and treated angina.
F
Peripheral arterial disease (PAD) includes both hospitalized and treated PAD.
G
The following secondary outcomes from ALLHAT are not included: cancer,
hospitalized for GI bleeding.
H
The following components of secondary outcomes was not included in this table:
angina (hospitalized).
I
A minority of study participants have missing values for these risk factors. The missing
values for these participants were imputed.
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Discussion

In a large, nationally dispersed RCT of antihypertensive therapy, we observed
significant variation in blood pressure control and cardiovascular outcomes according to
the socioeconomic context in which clinical care was provided. Participants receiving
care in the lowest income sites as compared with the highest income sites had
significantly worse blood pressure control with antihypertensive medications, irrespective
of medication study arm, and higher rates of heart failure hospitalizations, ESRD and
mortality, even after adjusting for demographic and clinical characteristics. These
disparities persisted in subgroup analyses of black participants and those living in the
South, populations that have previously been shown to have worse hypertensionassociated cardiovascular outcomes, demonstrating that socioeconomic context is
independently important.
Although the impact of socioeconomic context on health outcomes is known, the
differences in clinical outcomes in this study are notable because they occurred in the
context of a large RCT, which typically affords participants equal access to health care
resources by 1) assigning them to standardized protocols in which study medications are
provided free-of-charge, and 2) providing specific guidelines for the intensification of
medication and provision of follow-up visits. Moreover, although ALLHAT enrolled a
geographically and ethnically diverse population, only 8% of participants came from the
lowest income sites, whereas 38% came from the highest income sites, potentially
reducing the generalizability of trial findings to low socioeconomic populations and
opportunities to more fully understand the disparities observed in this analysis.
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The association between sociodemographic characteristics and hypertension is
already well-documented. Studies have shown that improvement in cardiovascular risk
factors over recent decades in the U.S. have disproportionately occurred among adults of
higher socioeconomic strata (14, 109). Moreover, RCTs of pharmacologic interventions
for hypertension have demonstrated an effect of person-level demographic factors, such
as race, gender and income, on cardiovascular outcomes, though not of community-level
factors (83, 85, 99, 104, 110). However, to date no studies have examined the influence
of socioeconomic context on outcomes resulting from antihypertensive treatment. While
the relationships between person-level factors and hypertension outcomes are important
to understand and address, inattention to the effect of community-level factors related to
socioeconomic context may obscure data that are important for achieving improved
cardiovascular outcomes.
Specifically, the differences in outcomes we report here may be a result of
differences in any number of factors: a community’s health behaviors (e.g., diet, exercise,
smoking, and alcohol trends), clinical factors (e.g., access to care, quality of care, visit
adherence, or medication adherence), or other aspects of the physical and social
environment (e.g., housing, access to healthy foods and exercise, neighborhood violence,
social cohesion), all of which may impact pharmacoeffectiveness. The disparities we
observed may also indicate that despite the efforts of RCTs to standardize treatment
protocols, clinical sites in low-resource areas may have fewer overall resources and
capabilities than those in wealthier areas. Unfortunately, existing methods are limited in
their ability to isolate the impact of these other factors on clinical outcomes in RCTs. To
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rectify this problem, future clinical trials could attempt to explicitly measure these
factors.
Notably, participants in the lowest income sites had lower visit adherence than
those in the highest income sites, though the reasons for this are uncertain. Visit
adherence may have a direct effect on outcomes, wherein attending visits more frequently
provides more opportunities to improve outcomes. Additionally, factors associated with
adherence to visits (e.g. access to transportation, health behaviors, physician-patient
relationship) may indirectly impact outcomes. Our exploratory analysis adjusting for six
year visit adherence supports the possibility that fidelity to the protocol may explain
some of the difference in outcomes between the two groups. However, differences in
blood pressure control were unchanged even after adjusting for visit adherence. In
addition, visit and medication adherence were actually highest in the second-lowest
income quintile, making it difficult to determine to what extent adherence varies by
socioeconomic context. Regrettably, in this study, medication adherence was
inadequately assessed and was missing in up to 1/3 of participants, limiting interpretation
of findings. Ultimately, to fully understand the importance of adherence on outcomes in
clinical trials, more rigorous and complete assessment of adherence is needed, especially
to the study medication.
Potentially related, participants in the lowest income sites were significantly less
likely to receive coronary revascularization, or be hospitalized or treated for angina. An
aggregate outcome, combined CVD (which contains coronary revascularization and
angina as subcomponents) was also less likely among participants in the lowest income
sites. These findings were contrary to our hypothesis that socioeconomic context could
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lead to greater cardiovascular morbidity and related procedural interventions. However,
given the racial and socioeconomic make-up of participants in low income sites, it is
plausible that these findings reflect differences in presentation by race (111) or in
utilization patterns related to cultural norms for seeking care, access to care, or other
unmeasured factors. Numerous studies have previously shown that patients who are black
or of lower socioeconomic status are less likely to receive procedures such as coronary
revascularization (112-114). Unfortunately, in this study design we are not able to discern
whether these outcomes are measuring the effect of true differences in cardiovascular
events or differences in access to or quality of care beyond the standardized protocol of
the trial.
Furthermore, we noted a substantial difference in blood pressure control, visit and
medication adherence, coronary revascularization, and hospitalized or treated angina
between the lowest income quintile and the other four income quintiles, which tended to
have greater similarities in outcomes. The median household income in the lowest
income quintile was $21,800; by comparison, the federal poverty level – the threshold or
minimum level of income one would need to secure the necessities of life – for a family
of 4 was $17,050 in the year 2000 (115). This suggests that participants in the lowest
income sites obtained care (and potentially lived) in some of the poorest counties in the
United States, where many people may not have access to sufficient resources to secure
these basic necessities. Similar to the federal poverty level, there may exist a threshold of
resources that a community must surpass in order for its inhabitants to be able to live and
maintain their health or well-being, and thus achieve hypertension outcomes similar to
those of less deprived communities. Although the existing literature has been unable to
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shed further light on this question, the relationship between area-level socioeconomic
deprivation and hypertension outcomes is likely more nuanced, in that different
communities may require different resources in order to thrive.
In addition, we attempted to separate the effects of race from socioeconomic
context by assessing socioeconomic groups within racial strata and found that the results
did not differ from the overall findings; however, participants in the lowest income sites
were more likely to be black, making it difficult to fully distinguish any association of
race with cardiovascular outcomes. Genetic factors may contribute to racial disparities in
these outcomes. For example, participants in the lowest income sites, many of whom
were minorities, had significantly higher risk for ESRD. Genetic studies have
demonstrated that there is a higher prevalence of a high-risk variant of the apoliprotein L1 (APOL1) gene in African-American populations, as compared to European-American
populations (116). The presence of this allele is associated with a higher risk of end-stage
kidney disease attributed to hypertension. Differences in clinical characteristics may also
play a role. Previous studies have shown that black participants are less likely to achieve
blood pressure control, even in the context of RCTs (including ALLHAT), possibly due
to difference in medication and visit adherence (85, 110, 117-119). Such racial disparities
in outcomes are well documented for other cardiovascular conditions, as well, with some
studies identifying economic and social barriers affecting blood pressure control in black
patients (60, 120-122). One such factor, residential neighborhood segregation has been
associated with changes in systolic blood pressure, indicating that there may be overlap
between individual factors such as race and contextual factors such as disparate
household incomes within a community (123).
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Additionally, structural racism leading to increased stress exposure and reactivity,
along with differences in quality of care may impact outcomes, though are seldom
assessed in RCTs (124). The United States has a long history of socioeconomic and racial
disparities, and there may be shared or unique structural disparities leading to these
differences that we may not be able to capture, given the limitations of existing clinical
trial data. Thus, other methodological approaches may be necessary to better and more
rigorously encapsulate the effect of these complex and interrelated disparities on health
outcomes.
Geographic location may also be important. Nearly all participants in the lowest
income sites lived in the South, consistent with studies dating back as far as the 1980s
which have shown that poverty rates have historically been higher in the South than in
the rest of the country (125). Prior studies from ALLHAT demonstrate that living in the
South predicted a lower likelihood of achieving blood pressure control as compared with
other U.S. and non-U.S. regions (85). This finding is consistent with a recent CDC report
that indicated worse hypertension control in Southern states thought to be part of the
“stroke belt” (119). Another secondary analysis of ALLHAT found that there were no
statistically significant differences in medication adherence among patients based on the
geographic region in which their clinical site was located (117). However, both of these
studies considered broad geographic regions encompassing many counties, rather than
singular counties. Other studies of hypertension and cardiovascular RCTs have evaluated
the effect of geographic region on study outcomes, but these studies were conducted at
the country level or at similarly broad regional geographic levels, potentially obscuring
heterogeneity within large geographic areas (126-135). Moreover, many RCTs do not
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enroll enough patients to be able to study geographic effect at a more granular level. Still,
these studies are consistent with our findings and demand that more work be done to
understand the nature of regional disparities in hypertension outcomes, which persist
even within large, robust RCTs.

Limitations
There are several limitations to this study. First, it is possible that the county in
which a clinical site is located may differ from a participant’s county of residence. While
distance from residence to medical care varies by rurality, in an RCT, we assumed that
people who decided to participate in the study would live reasonably close. More
importantly, counties differ in size and may comprise several socioeconomic contexts;
though we did not have data to study the effect of socioeconomic context at a more
granular level (such as census tract), our use of county level measures would tend to bias
our findings towards the null, as it dilutes the true income status of a community. Third,
area income may not be a perfect indicator of social risk factors, such as neighborhood
violence or access to healthy foods, which can impact health outcomes. However,
county-level analyses can serve as a reasonable proxy for the amount of resources
available in a community and can be important for directing policy interventions and
resources.
Fourth, though it is the largest completed randomized hypertension trial, the data
from ALLHAT is now nearly 20 years old and progress may have been made in the
interim in addressing disparities in hypertension outcomes. Fifth, although the population
enrolled in ALLHAT was indeed socio-demographically and geographically diverse, only
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12% of U.S. counties were represented by the clinical sites in this study, potentially
limiting the generalizability of our findings. Sixth, although we performed subgroup
analyses for black participants and those living in the South, we were unable to perform
similar stratified analyses for participants of other races or those living in other regions.
This was due to an insufficient number of participants with these identifiers in either the
top or bottom income quintiles. Given that clinical sites in the South were more likely to
be low income and enroll black participants, we may not have been able to fully discern
the effects of race and geography from socioeconomic context. Seventh, because we did
not have access to unique location or clinic identifiers for each patient, we were unable to
account for correlation of outcomes within an area. Though this may have resulted in
overnarrow confidence intervals, none of our key findings were marginal and thus it is
reasonable to expect that they would have been unchanged even if we had accounted for
such correlation. Last, data on medication adherence was insufficient to include in our
secondary analyses, making it more difficult to delineate the extent to which medication
adherence may have attenuated outcomes. However, medication adherence was likely
influenced by contextual factors which were not measured in this trial.

Conclusions
Observational studies have previously shown that socioeconomic context is
associated with hypertension and worse hypertension outcomes. This study extends these
findings to the largest randomized clinical trial of antihypertensive treatment, in which
participants had equal access to resources afforded by such a trial. Although participants
across income strata were appropriately randomized to the main treatment arms, we
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observed disparities in participant characteristics and visit and medication adherence
across socioeconomic strata, and found that study enrollment favored participants from
higher socioeconomic strata. We also observed disparities in blood pressure control, heart
failure morbidity, ESRD, all-cause mortality and coronary revascularization across
socioeconomic strata, even after controlling for medication treatment arm, demographics,
and clinical characteristics; furthermore, there may be some suggestion that visit
adherence may have impacted outcomes.
These results bring into question whether the anticipated benefits of
antihypertensive therapy, derived from landmark trials such as ALLHAT, are truly
generalizable to all communities within the U.S. The heterogeneity in treatment effect by
socioeconomic context observed in this study is important knowledge because it may
have implications for guideline recommendations and clinical decision making. Our
findings thus underscore the importance of measuring socioeconomic context in RCTs
and suggest the need to develop better methods to capture contextual data and understand
their association with outcomes, so that findings from clinical trials can inform treatment
guidelines and also be generalized to populations encountered in everyday clinical
practice.
Moreover, to attain equity in hypertension outcomes, we must not only work to
implement guideline recommendations for antihypertensive therapy, but we must also
work within communities to address the underpinnings of disparities by socioeconomic
context. In the context of RCTs, investigators of future trials of antihypertensive
medications should make more concerted efforts to recruit socioeconomically diverse
participants or offer additional resources to participants in disadvantaged areas to
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eliminate disparities in trial outcomes and ensure that study results are meaningful for
these populations. In clinical practice, physicians could offer additional support or
resources to patients from under-resourced communities seeking treatment for
hypertension; physicians and researchers might encourage elected leaders and
professional societies at the local, state, and federal levels to focus on contextual factors
impacting cardiovascular outcomes. For example, public policy efforts and grants could
focus on addressing the underlying factors that disproportionally affect low
socioeconomic communities today and which may relate to hypertension and
cardiovascular outcomes, including improving local infrastructure to support exercise and
access to healthy foods, reduce stress, improve neighborhood safety, and increase access
to medicines, primary care, mental health resources, and more. Finally, recognition of
and sensitivity to the contextual socioeconomic factors influencing response to
antihypertensive medication can support more effective, patient- and communitycentered approaches that go beyond the guidelines to manage hypertension.
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